BC	breast cancer
BCS	breast conserving surgery
CBs	clinical biomarkers
CE-MRI	contrast-enhanced magnetic resonance imaging
CI	confidence interval
DICOM	digital imaging and communications in medicine
DW-MRI	diffusion-weighted magnetic resonance imaging
EC	epirubicin/cyclophosphamide
ESMO	European society for medical oncology
HER2	human epidermal growth factor receptor 2
IV	intravenously
MIP	maximum intensity projection
MRI	magnetic resonance imaging
NAC	neoadjuvant chemotherapy
PARP	poly ADP ribose polymerase
pCR	pathological complete response
PD	pharmacodynamics
PDE	partial differential equation
PET/CT	positron emission tomography/computed tomography
PK	pharmacokinetics
ROI	regions of interest
STL	stereolithography
TNBC	triple-negative breast cancer
TP	true positive
VBs	virtual biomarkers
18FDG	18F-fluorodeoxyglucose
Nomenclature
The following nomenclatures are used in this manuscript:
AD	absolute volume difference, cm3
D	diffusion coefficient, m2/s
f	temporal administration pattern of therapy, or modulation function, 1/d
K	carrying capacity of the biological matrix, dimensionless
md	administered mass flow rate, determined on personalized basis, mol/m3 s
rc	biological conversion rate, 1/s
R	source term in Equations (2) and (3), 1/s
t	time, d
V*	computed lesion volume, cm3
V	measured lesion volume, cm3
x	coordinate vector, cm
Greek
∆t	duration, d
∆V	residual lesion volume to remove after NAC, cm3
ϵPD	drug efficiency (effect of drug on body), 1/s
ϵPK	drug clearance (effect of body on drug), 1/s
∂Ωe	surface, m2
ϕc	normalized cancer cell density or volume, dimensionless
ϕd	normalized drug concentration, dimensionless
Ω	computational volume, cm3
Subscripts
0	nominal, ROI
c	cancer
d	drug
e	interface with the environment
i	initial, starting time
j	drug counter
s	surgical